Study guide
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items
NCRA Oncology Data Specialist ODS-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters
1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish
2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws
2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority
3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance
3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance
4 Chapter 4: Registry Organization, Staffing & Information Systems
4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning
5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement
5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)
6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality
6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)
7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics
7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data
8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
9 Chapter 9: Casefinding & Reportability
9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"
10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators
10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More
11 Chapter 11: Class of Case, Key Dates & Case Identifiers
11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
12 Chapter 12: Follow-Up, Vital Status & Recurrence
12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade
13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules
14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS
16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items
Key Takeaways Explain This Topic AI
T describes the primary tumor, N the regional lymph nodes and M distant metastasis; TX and NX mean they cannot be assessed, and MX is no longer a valid category.
When there is doubt between two categories, AJCC's general rule is to assign the lower, less advanced category.
Prefixes identify the classification: c clinical, p pathological, yc and yp after neoadjuvant therapy, r recurrence or retreatment, and a autopsy; suffixes include (m) for multiple tumors, (sn) sentinel node, (f) FNA or core biopsy, and (i+) or (mol+) for isolated tumor cells.
pM0 is not used except at autopsy; if distant metastasis is not proven microscopically, pathological staging uses cM0, and microscopic confirmation of metastasis gives pM1 in either time frame.
STORE requires AJCC TNM items for Class of Case 10–22; code 88 is only for site and histology combinations or in situ tumors that AJCC does not stage, and 99 is for a stage group that cannot be determined.
Last updated: September 2026
Why TNM
AJCC staging gives physicians and registries a shared language for prognosis, treatment planning and outcome comparison. CoC requires accredited programs to record AJCC staging using the edition in effect for the diagnosis year. That is the AJCC Cancer Staging Manual, 8th edition for 2018 and later, plus Version 9 chapters as AJCC releases them for individual sites. For example, cervix Version 9 applies to 2021 and later diagnoses, and lung Version 9 to 2025 and later (Section 15.4).
The three categories
Category Describes Typical values
T Primary tumor size and extension TX (cannot be assessed), T0 (no evidence of primary), Tis (in situ), T1–T4 with subcategories
N Regional lymph nodes NX (cannot be assessed), N0, N1–N3 with subcategories
M Distant metastasis cM0, cM1 (clinical evidence), pM1 (microscopically confirmed), with subcategories such as M1a–M1c
MX is not used. It was eliminated in the 7th edition. If there is no clinical evidence of distant metastasis, the category is cM0 .
Each chapter defines its own regional lymph nodes. Nodes that are not regional count as M disease. For example, contralateral axillary nodes in breast cancer are M1.
Direct extension of the primary tumor into a regional node counts as node involvement.
General rules
Uncertainty rule: if it is unclear which of two categories applies, assign the lower (less advanced) category. The same applies to stage groups.
Multiple synchronous tumors in one organ: assign T from the tumor with the highest T, and show multiplicity with (m) or the number of tumors, for example T2(m) or T2(3). Some chapters, such as thyroid and lung, have their own multiplicity rules.
Tumor size: use the chapter's rounding rules. Most chapters round to the nearest millimeter. For example, a breast tumor measuring 1.2 mm is rounded to 2 mm, so it is not T1mi.
Stage groups combine T, N and M, and in some chapters also prognostic factors :
- grade, ER, PR, HER2 and multigene scores for breast;
- PSA and Grade Group for prostate;
- serum markers (S) for testis;
grade for some other sites.
All information in the time frame is used, including information from other facilities.
Prefixes
- Prefix Classification
- c Clinical: before treatment (Section 15.2)
- p Pathological: clinical information plus surgical resection findings, with no neoadjuvant therapy
- yc Post-therapy clinical: after neoadjuvant therapy or primary systemic or radiation therapy, before surgery
- yp Post-therapy pathological: surgery after neoadjuvant therapy
- r Recurrence or retreatment staging. It does not replace the original stage in the registry
- a Autopsy: cancer first found at autopsy
- Suffixes and descriptors
- Descriptor Meaning
- (m) Multiple primary tumors in one site
- (sn) N assessed by sentinel node biopsy only, for example pN1(sn)
- (f) N assessed by FNA or core needle biopsy only, for example cN1(f)
(i+) Isolated tumor cells: 0.2 mm or smaller, or 200 cells or fewer in breast. In most chapters ITCs are categorized as N0(i+)
- (mol+) Tumor detected only by molecular methods
- Pathological classification without a complete resection
pT usually needs resection of the primary tumor. Microscopic confirmation of the highest T category (for example, a biopsy showing invasion of an adjacent organ that makes the tumor T4) can support pT.
pN needs removal of nodes adequate to show the N category. Microscopic confirmation of a node in the highest N category (for example, a biopsy of a node that defines N3) is enough for pN.
pM1 means distant metastasis is microscopically confirmed . If pM1 is proven during the clinical time frame, the case can be assigned stage IV in both the clinical and pathological classifications.
pM0 is not used , except at autopsy. When a resection shows no distant disease and none was proven microscopically, the pathological classification uses cM0 .
STORE registry items
- Classification T N M Stage group
- Clinical 1001 1002 1003 1004
- Pathological 1011 1012 1013 1014
- Post-therapy pathological (yp) 1021 1022 1023 1024
- Post-therapy clinical (yc), 2021+ 1062 onward
STORE rules:
The clinical and pathological T, N and M items must be assigned for Class of Case 10–22 . Clinical M is strongly recommended for Class 00 when the workup allows.
Record the stage the managing physician documents. If none is recorded, the registrar assigns it from the best available information, without needing to contact the physician.
Code 88 is for a site and histology combination not defined in the current AJCC edition, and for in situ tumors that AJCC does not stage . It is not a general "not applicable" code for a classification whose criteria were not met.
Code 99 is for a stage group when the TNM combination, together with any required prognostic factors, does not produce a valid stage group.
Values are left-justified in 15-character fields, using AJCC's published code labels (for example, "cT2a").
Worked example
A 2.4 cm invasive breast carcinoma with a positive sentinel node (macrometastasis 3 mm, 1 of 2 nodes) and no distant work-up findings is resected without neoadjuvant therapy. The result is pT2 pN1a(sn) cM0 . The pathological M category is cM0 , not pM0. The prognostic stage group then depends on grade, ER, PR and HER2 (Section 15.3).